Trial reportPloS one2014
Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Antibiotics for the induction and maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2022Pooled it
- Antibiotic combination therapy for the induction and maintenance of remission in patients with ulcerative colitis.Bioscience of microbiota, food and health · 2025Article
- Article
- Combination treatment of inflammatory bowel disease: Present status and future perspectives.World journal of gastroenterology · 2024Article
- The stimulatory effect of fusobacteria on dendritic cells under aerobic or anaerobic conditions.Scientific reports · 2022Article
- Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood.International journal of molecular sciences · 2021Review
- Use of Antibiotics and Probiotics Reduces the Risk of Metachronous Gastric Cancer after Endoscopic Resection.Biology · 2021Article
- Article
- Long-term outcomes of antibiotic combination therapy for ulcerative colitis.Therapeutic advances in chronic disease · 2021Article
- Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota.Frontiers in immunology · 2020Review
- Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.Inflammatory bowel diseases · 2019Article
- Consensus report: faecal microbiota transfer - clinical applications and procedures.Alimentary pharmacology & therapeutics · 2017Review
- Different Effects of Three Selected Lactobacillus Strains in Dextran Sulfate Sodium-Induced Colitis in BALB/c Mice.PloS one · 2016Article
- Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches.Current treatment options in gastroenterology · 2015Article
- Elemental diets role in treatment of high ileostomy output and other gastrointestinal disorders.Gastroenterology and hepatology from bed to bench · 2015Article
- Fusobacterium varium in ulcerative colitis: is it population-based?Digestive diseases and sciences · 2015Article
- The hygiene hypothesis: current perspectives and future therapies.ImmunoTargets and therapy · 2015Review
- Nested PCR Biases in Interpreting Microbial Community Structure in 16S rRNA Gene Sequence Datasets.PloS one · 2015Article
- The multifaceted role of commensal microbiota in homeostasis and gastrointestinal diseases.Journal of immunology research · 2015Review
- Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous work has demonstrated that intestinal bacteria, such as Fusobacterium varium (F. varium), contribute to the clinical activity in ulcerative colitis (UC); thus, an antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole (ATM)) against F. varium can induce and maintain UC remission. Therefore, we investigated whether ATM therapy induces a long-term alteration of intestinal microbiota in patients with UC. Patients with UC were enrolled in a multicenter, randomized, double-blind, placebo-controlled study. Biopsy samples at the beginning of the trial and again at 3 months after treatment completion were randomly obtained from 20 patients. The terminal restriction fragment length polymorphism (T-RFLP) in mucosa-associated bacterial components was examined to assess the alteration of the intestinal microbiota. Profile changes of T-RFLP in mucosa-associated bacterial components were found in 10 of 12 patients in the treatment group and in none of 8 in the placebo group. Dice similarity coefficients using the unweighted pair group method with arithmetic averages (Dice-UPGMA) confirmed that the similarity of mucosal microbiota from the descending colon was significantly decreased after the ATM therapy, and this change was maintained for at least 3 months. Moreover, at 3 months after treatment completion, the F. varium/β-actin ratio, examined by real-time PCR using nested PCR products from biopsy samples, was reduced less than 40% in 8 of 12 treated patients, which was higher, but not significantly, than in 4 of 8 patients in the placebo group. Together, these results suggest that ATM therapy induces long-term alterations in the intestinal microbiota of patients with UC, which may be associated, at least in part, with clinical effects of the therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.